We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | |
|---|---|---|---|---|---|
| -0.39 | -0.43% | 91.23 | 91.00 | 91.62 |
| High Price | Low Price | Open Price | Shares Traded | Last Trade |
|---|---|---|---|---|
| 91.72 | 89.63 | 91.38 | 1,682,358 | 16:40:00 |
| Date | Time | Source | Headline |
|---|---|---|---|
| 23/1/2024 | 11:05 | DJN | Sanofi to Buy Assets From Inhibrx in Deal Valued at Up to $2.2 Billion --.. |
| 09/1/2024 | 07:14 | DJN | Sanofi Names Brian Foard Head of Specialty-Care Unit |
| 21/12/2023 | 07:25 | DJN | Sanofi Ends Drug Program After Late-Stage Trial in Lung Cancer Fails |
| 19/12/2023 | 12:28 | DJN | Innate Pharma Shares Rise after Sanofi Exercises Licensing Option |
| 11/12/2023 | 22:18 | DJN | Sanofi Terminates Agreement with Maze Therapeutics Following FTC Opposition |
| 11/12/2023 | 06:50 | DJN | Sanofi Sees Improvement in Trial Results of Cancer Drug Sarclisa |
| 07/12/2023 | 07:34 | DJN | Sanofi Myeloma Drug Sarclisa Met Primary Goal in Late-Stage Trial |
| 07/12/2023 | 07:20 | DJN | Sanofi Sees Annual Sales From New Pharma Assets Above $10.8 Billion by 2030 |
| 06/12/2023 | 13:20 | DJN | Trending: Merck's Multiple Sclerosis Drug Misses Expectations in Late-Stage.. |
| 06/12/2023 | 10:14 | DJN | Merck Shares Slump After Multiple Sclerosis Drug Fails in Late-Stage Trials |
1 Year Sanofi Chart |
Intraday Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
